tbuckley/cabot-search huggingface dataset:
Retraction: Nuclear Factor-κB p65 Mediates Tumor Necrosis Factor α-induced Nuclear Translocation of Telomerase Reverse Transcriptase Protein
Authors: Masaharu Akiyama, Teru Hideshima, Toshiaki Hayashi, Yu-Tzu Tai, Constantine S. Mitsiades, Nicholas Mitsiades, Dharminder Chauhan, Paul Richardson, Nikhil C. Munshi, Kenneth C. Anderson
Journal: Cancer Research (2024)

This article (1) has been retracted at the request of the authors.There are concerns about the reliability of certain data arising from errors in the assembly of Fig. 2. In Fig. 2A, the image used to represent hTERT in lane 1 of the TNFa group was flipped horizontally and used in lane 3 to represent a different sample at a distinct time point.In Fig. 2B, the same image was used to represent a-tubulin in each of the three distinct treatment groups.In Fig. 2B, the same image was used in lanes 1 and 2 of the TNFaþSN-50 group to represent hTERT expression in the cytoplasm in different samples at distinct timepoints.
Retraction: Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications
Authors: Yu-Tzu Tai, Laurence P. Catley, Constantine S. Mitsiades, Renate Burger, Klaus Podar, Reshma Shringpaure, Teru Hideshima, Dharminder Chauhan, Makoto Hamasaki, Kenji Ishitsuka, Paul Richardson, Steven P. Treon, Nikhil C. Munshi, Kenneth C. Anderson
Journal: Cancer Research (2024)

This article (1) has been retracted at the request of the authors.There are concerns about the reliability of certain data arising from errors in the assembly of Fig. 2. In Fig. 2A, the same image was used in lanes 2-5 to represent lkBa in cells treated with SGN-40 and in lanes 1-4 to represent lkBa in cells treated with sCD40L.In Fig. 2B, the same image was used in lanes 2 and 5 to represent pAKT in distinct samples and treatment conditions.
Selected Articles from This Issue
Journal: Clinical Cancer Research (2024)

Highlights| March 15 2024 Selected Articles from This Issue Author & Article Information Online ISSN: 1557-3265 Print ISSN: 1078-0432 ©2024 American Association for Cancer Research2024American Association for Cancer Research Clin Cancer Res (2024) 30 (6): 1071. https://doi.org/10.1158/1078-0432.CCR-30-6-HI Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record March 15 2024 Citation Selected Articles from This Issue. Clin Cancer Res 15 March 2024; 30 (6): 1071. https://doi.org/10.1158/1078-0432.CCR-30-6-HI Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search In patients with unresectable stage III non-small cell lung cancer (NSCLC), the standard of care is concurrent chemoradiotherapy (CCRT) followed by durvalumab therapy within 1 to 42 days after CCRT completion. Preclinical studies have demonstrated that concomitant administration of CCRT and immunotherapy led to increased survival rates compared to sequential administration; however, simultaneous CCRT and immunotherapy treatment poses safety risks in patients. The optimal timeline for initiating immunotherapy after chemoradiotherapy has yet to be established. In this phase II study, Nakamichi and colleagues investigated the safety and efficacy of beginning durvalumab treatment immediately after chemoradiotherapy completion in patents with unresectable stage III NSCLC. The observed adverse events (AEs) were similar to previously reported AEs, and no unexpected AEs occurred. The response was encouraging, with the authors reporting an objective response rate of 78.7%, a 1-year progression-free survival (PFS) rate of 75.0%, and a median PFS of 14.2 months from registration.... You do not currently have access to this content.
Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant‐level pooled analysis of <scp>DAPA‐HF</scp> and <scp>DELIVER</scp>
Authors: Alexander Peikert, Muthiah Vaduganathan, Brian L. Claggett, Ian J. Kulac, Alberto Foà, Akshay S. Desai, Pardeep S. Jhund, Jaclyn Carberry, Carolyn S.P. Lam, Mikhail N. Kosiborod, Silvio E. Inzucchi, Felipe A. Martinez, Rudolf A. de Boer, Adrian F. Hernandez, Sanjiv J. Shah, Lars Køber, Piotr Ponikowski, Marc S. Sabatine, Magnus Petersson, Anna Maria Langkilde, John J.V. McMurray, Scott D. Solomon
Journal: European Journal of Heart Failure (2024)

Abstract Aims Patients with heart failure (HF) and history of myocardial infarction (MI) face a higher risk of disease progression and clinical events. Whether sodium–glucose cotransporter 2 inhibitors may modify clinical trajectory in such individuals remains incompletely understood. Methods and results The DAPA‐HF and DELIVER trials compared dapagliflozin with placebo in patients with symptomatic HF with left ventricular ejection fraction (LVEF) ≤40% and &gt; 40%, respectively. In this pooled participant‐level analysis, we assessed efficacy and safety outcomes by history of MI. The primary outcome in both trials was the composite of cardiovascular death or worsening HF. Of the total of 11 007 patients, 3731 (34%) had a previous MI and were at higher risk of the primary outcome across the spectrum of LVEF in covariate‐adjusted models (hazard ratio [HR] 1.12, 95% confidence interval [CI] 1.02–1.24). Dapagliflozin reduced the risk of the primary outcome to a similar extent in patients with (HR 0.83, 95% CI 0.72–0.96) and without previous MI (HR 0.76, 95% CI 0.68–0.85; p i nteraction = 0.36), with consistent benefits on key secondary outcomes as well. Serious adverse events did not occur more frequently with dapagliflozin, irrespective of previous MI. Conclusion History of MI confers increased risks of adverse cardiovascular outcomes in patients with HF across the LVEF spectrum, even among those with preserved ejection fraction. Dapagliflozin consistently and safely reduces the risk of cardiovascular death or worsening HF, regardless of previous MI.
Author Correction: The DExD/H-box helicase Dicer-2 mediates the induction of antiviral activity in drosophila
Authors: Safia Deddouche, Nicolas Matt, Aidan Budd, Stefanie Mueller, Cordula Kemp, Delphine Galiana-Arnoux, Catherine Dostert, Christophe Antoniewski, Jules A. Hoffmann, Jean-Luc Imler
Journal: Nature Immunology (2024)
Differential in vivo roles of Mpl cytoplasmic tyrosine residues in murine hematopoiesis and myeloproliferative disease
Authors: Kira Behrens, Maria Kauppi, Elizabeth M. Viney, Andrew J. Kueh, Craig D. Hyland, Tracy A. Willson, Liam Salleh, Carolyn A. de Graaf, Jeffrey J. Babon, Marco J. Herold, Nicos A. Nicola, Warren S. Alexander
Journal: Leukemia (2024)

Abstract Thrombopoietin (Tpo), which binds to its specific receptor, the Mpl protein, is the major cytokine regulator of megakaryopoiesis and circulating platelet number. Tpo binding to Mpl triggers activation of Janus kinase 2 (Jak2) and phosphorylation of the receptor, as well as activation of several intracellular signalling cascades that mediate cellular responses. Three tyrosine (Y) residues in the C-terminal region of the Mpl intracellular domain have been implicated as sites of phosphorylation required for regulation of major Tpo-stimulated signalling pathways: Mpl-Y565, Mpl-Y599 and Mpl-Y604. Here, we have introduced mutations in the mouse germline and report a consistent physiological requirement for Mpl-Y599, mutation of which resulted in thrombocytopenia, deficient megakaryopoiesis, low hematopoietic stem cell (HSC) number and function, and attenuated responses to myelosuppression. We further show that in models of myeloproliferative neoplasms (MPN), where Mpl is required for pathogenesis, thrombocytosis was dependent on intact Mpl-Y599. In contrast, Mpl-Y565 was required for negative regulation of Tpo responses; mutation of this residue resulted in excess megakaryopoiesis at steady-state and in response to myelosuppression, and exacerbated thrombocytosis associated with MPN.
NCI Cancer Research Data Commons: Core Standards and Services
Authors: Arthur Brady, Amanda Charbonneau, Robert L. Grossman, Heather H. Creasy, Robinette Renner, Todd Pihl, John Otridge, Erika Kim, Jill S. Barnholtz-Sloan, Anthony R. Kerlavage
Journal: Cancer Research (2024)

Abstract The NCI Cancer Research Data Commons (CRDC) is a collection of data commons, analysis platforms, and tools that make existing cancer data more findable and accessible by the cancer research community. In practice, the two biggest hurdles to finding and using data for discovery are the wide variety of models and ontologies used to describe data, and the dispersed storage of that data. Here, we outline core CRDC services to aggregate descriptive information from multiple studies for findability via a single interface and to provide a single access method that spans multiple data commons. See related articles by Wang et al., p. 1388, Pot et al., p. 1396, and Kim et al., p. 1404
NCI Cancer Research Data Commons: Lessons Learned and Future State
Authors: Erika Kim, Tanja Davidsen, Brandi N Davis-Dusenbery, Alexander Baumann, Angela Maggio, Zhaoyi Chen, Daoud Meerzaman, Esmeralda Casas-Silva, David Pot, Todd Pihl, John Otridge, Eve Shalley, Jill S. Barnholtz-Sloan, Anthony R. Kerlavage
Journal: Cancer Research (2024)

Abstract More than ever, scientific progress in cancer research hinges on our ability to combine datasets and extract meaningful interpretations to better understand diseases and ultimately inform the development of better treatments and diagnostic tools. To enable the successful sharing and use of big data, the NCI developed the Cancer Research Data Commons (CRDC), providing access to a large, comprehensive, and expanding collection of cancer data. The CRDC is a cloud-based data science infrastructure that eliminates the need for researchers to download and store large-scale datasets by allowing them to perform analysis where data reside. Over the past 10 years, the CRDC has made significant progress in providing access to data and tools along with training and outreach to support the cancer research community. In this review, we provide an overview of the history and the impact of the CRDC to date, lessons learned, and future plans to further promote data sharing, accessibility, interoperability, and reuse. See related articles by Brady et al., p. 1384, Wang et al., p. 1388, and Pot et al., p. 1396
Stress in the microbiome-immune crosstalk
Authors: Eléonore Beurel
Journal: Gut Microbes (2024)

The gut microbiota exerts a mutualistic interaction with the host in a fragile ecosystem and the host intestinal, neural, and immune cells. Perturbations of the gastrointestinal track composition after stress have profound consequences on the central nervous system and the immune system. Reciprocally, brain signals after stress affect the gut microbiota highlighting the bidirectional communication between the brain and the gut. Here, we focus on the potential role of inflammation in mediating stress-induced gut-brain changes and discuss the impact of several immune cells and inflammatory molecules of the gut-brain dialogue after stress. Understanding the impact of microbial changes on the immune system after stress might provide new avenues for therapy.
BJD Reviewers January 2023–December 2023
Authors: Pim Aarts, Ayman Abdelmaksoud, Riichiro Abe, Katrina Abuabara, Jonas Adalsteinsson, Adewole Adamson, Nikki Adler, Shehla Admani, Indra Adrianto, Eugenia Agut-Busquet, Malin Ahlström, Ahmed Glindvad, Alia Ahmed, Ammar Ahn, Jiyoung Akilov, Oleg Akiyama, Masashi Akiyama, Tasuku Alabas, Oras Al-Adwi, Yehya Alberti-Violetti, Silvia Albrecht, Joerg Alexander, Matthew Alhusayen, Raed Amatore, Florent Amber, Kyle Ambur, Austin Amerio, Paolo Andrade, Danieli Castro De Oliveira, Michael Arents, Bernd Arkin, Lisa Armato, Ubaldo Armour, Katherine Asero, Riccardo Asfour, Leila Atzmony, Lihi Atzori, Laura Austin, Evan Bagot, Magdalena Claeson, Louise Clark, Laura Coates, Arnon Cohen, Fiona Collier, John Common, Andrea Conti, Ana Copaescu, Antonio Costanzo, Ian Coulson, Fiona Cowdell, Anne Cust, Adnan Custovic, Johan Dalen, Florence Dalgard, Aoife Daly, Giovanni Damiani, Nick Dand, Roxana Daneshjou, Maryam Daneshpazhooh, Steven Daveluy, Michael Davies, Olivia Davies, Marianne De Brito, Marjolein De Bruin, Guzman De, Cristina Strong, Dekker Deacon, James Decaprio, Veronique Del Marmol, Robert Dellavalle, Julie Delyon, Olivier Dereure, Clio Dessinioti, Veronica Carlo, G Zenzo, Janine Dickinson, Brian Diffey, Florentia Dimitriou, Jacqueline Dinnes, Thomas Dirschka, Matthew Dizon, Gabor Dobos, Belen Dofitas, Sunil Dogra, Heather Draper, Corinna Dressler, Aaron Drucker, Amanda Drury, Koen Dudink, Nicolas Dupin, Jean Dusingize, Aurélie Du-Thanh, Jan Dutz, Judith Dyson, Ewan Eadie, Emily Heredia, Mees Egeler, Celeste Eggermont, Liv Eidsmo, Daniel Eisen, Mary-Ann El Sharouni, Sabina Illi, Daniela Impellizieri, Saskia Ingen-Housz-Oro, Gareth Inman, Dimitris Ioannides, Marlene Isaksson, Taisuke Ito, Jared Jagdeo, Manu Jain, Alaina James, Monika Janda, Rachael Jarrett, Sue Jessop, Yi Ji, Antonio Ji-Xu, Jin Seong, Emma Johansson, Pascal Joly, Constanze Jonak, Nathalie Jonca, Owain Jones, Benjamin Kaffenberger, Sunil Kalia, Masahiro Kamata, Johan Kappelin, Giorgos Karakousis, Sarolta Kárpáti, Manfred Kayser, Niamh Kearney, Vaughan Keeley, Anju Keetharuth, Thibault Kervarrec, Naram Khalayli, Sabrina Khan, Sidra Khan, Leila Khoja, Do-Young Kim, Soo Kim, Jaehwan Kim, Jihee Kim, Jong Kim, Minsung Kim, Brett King, Misaki Kinoshita-Ise, Brian Kirby, Joslyn Kirby, Lisa Kirby, Yohei Kirino, Dimitra Kiritsi, Gudula Kirtschig, Yasuo Kitajima, Harald Kittler, Maija Kiuru, Rune Andersen, A Klausegger, Christine Kleyn, Robert Knobler, Justin Ko, Tai-Ming Ko, Laura Kobyletzki, Emek Von Kocatürk, Ulrich Koller, Michael Kolodney, Michihiro Kono, Tuomas Konttinen, Neil Korman, Eva Korte, Jan Kottner, Emily Kozera, Matthew Krantz, Jean Krutmann, Akiharu Kubo, Joerg Kupfer, Nicholas Kurtansky, Zhenli Kwan
Journal: British Journal of Dermatology (2024)
Author Correction: Small-molecule-mediated control of the anti-tumour activity and off-tumour toxicity of a supramolecular bispecific T cell engager
Authors: Ningqiang Gong, Xuexiang Han, Lulu Xue, Margaret M. Billingsley, Xisha Huang, Rakan El-Mayta, Jingya Qin, Neil C. Sheppard, Carl H. June, Michael J. Mitchell
Journal: Nature Biomedical Engineering (2024)
The landscape for rare diseases in 2024
Authors: None The Lancet Global Health
Journal: The Lancet Global Health (2024)

By definition, rare diseases affect a small number of individuals (fewer than 1 in 2000 people in any WHO region); yet, with more than 7000 types of rare disease in existence, the burden worldwide is not insignificant. To date, approximately 300 million people live with rare diseases. Such individuals are often a neglected and marginalised group, especially those in low-income and middle-income countries. Around 80% of rare diseases have a genetic cause, almost 70% of which present in childhood; about 95% lack approved treatments; the average time for an accurate diagnosis is 4·8 years; and about 30% of children with a rare disease die before age 5 years.
A guide to improving the design and analysis of observational studies on the long-term safety of topical corticosteroids
Authors: Aaron M Drucker, Peter C Austin, Jane Harvey, Stephanie J Lax, Mina Tadrous, Kim S Thomas
Journal: British Journal of Dermatology (2024)

Despite a long track-record of use, patients and clinicians continue to have concerns about the safety of topical corticosteroids (TCS). Observational studies in routinely collected health data provide an opportunity to address those concerns but are challenging to conduct in a way that minimizes bias and confounding. We review challenges and potential solutions for the conduct of observational studies on the long-term safety of TCS.
Interactions between skin-resident dendritic and Langerhans cells and pain-sensing neurons
Authors: Natalie C Wilcox, Golnar Taheri, Katherine Halievski, Sebastien Talbot, Jaqueline R Silva, Nader Ghasemlou
Journal: Journal of Allergy and Clinical Immunology (2024)

Various immune cells in the skin contribute to its function as a first line of defense against infection and disease, and the skin's dense innervation by pain-sensing sensory neurons protects the host against injury or damage signals. Dendritic cells (DCs) are a heterogeneous population of cells that link the innate immune response to the adaptive response by capturing, processing, and presenting antigens to promote T-cell differentiation and activation. DCs are abundant across peripheral tissues, including the skin, where they are found in the dermis and epidermis. Langerhans cells (LCs) are a DC subset located only in the epidermis; both populations of cells can migrate to lymph nodes to contribute to broad immune responses. Dermal DCs and LCs are found in close apposition with sensory nerve fibers in the skin and express neurotransmitter receptors, allowing them to communicate directly with the peripheral nervous system. Thus, neuroimmune signaling between DCs and/or LCs and sensory neurons can modulate physiologic and pathophysiologic pathways, including immune cell regulation, host defense, allergic response, homeostasis, and wound repair. Here, we summarize the latest discoveries on DC- and LC-neuron interaction with neurons while providing an overview of gaps and areas not previously explored. Understanding the interactions between these 2 defence systems may provide key insight into developing therapeutic targets for treating diseases such as psoriasis, neuropathic pain, and lupus.
Shoring up the foundations of pathogen surveillance
Authors: None The Lancet Microbe
Journal: The Lancet Microbe (2024)

In February, WHO announced the creation of a "catalytic grant fund" to support work into pathogen genomic surveillance. The emphasis is on supporting projects in low-income and middle-income countries that explore how to accelerate the expansion of surveillance. The early financing of the fund comes from familiar philanthropic sources: the Bill & Melinda Gates Foundation, The Rockefeller Foundation, and Wellcome. Given the relatively small size of this fund, US$4 million, the need for three high-profile donors is a little surprising.
Deucrictibant for angioedema due to acquired C1-inhibitor deficiency: A randomized-controlled trial
Authors: Remy S Petersen, Lauré M Fijen, Johannes P Kelder, Danny M Cohn
Journal: Journal of Allergy and Clinical Immunology (2024)

Angioedema due to acquired C1-inhibitor deficiency is a very rare but serious disease, with an estimated prevalence of 1 per 500,000 persons. There are no approved therapies to treat or prevent angioedema swelling in patients with this condition. Deucrictibant is a specific, orally bioavailable, competitive antagonist of the bradykinin B2 receptor currently under investigation for hereditary angioedema.
Safety and efficacy of continuous subcutaneous levodopa–carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial
Authors: Alberto J Espay, Fabrizio Stocchi, Rajesh Pahwa, Alberto Albanese, Aaron Ellenbogen, Joaquim J Ferreira, Nir Giladi, Tanya Gurevich, Sharon Hassin-Baer, Jorge Hernandez-Vara, Stuart H Isaacson, Karl Kieburtz, Peter A LeWitt, Lydia Lopez-Manzanares, C Warren Olanow, Werner Poewe, Harini Sarva, Tami Yardeni, Liat Adar, Laurence Salin, Nelson Lopes, Nissim Sasson, Ryan Case, Olivier Rascol, Mitra Afshari, Alexander Amelin, David Arkadir, Samih Badarny, Ernest Balaguer Martinez, Andrzej Bogucki, James Boyd, Laura Buyan Dent, Camille Carroll, Kallol Ray Chaudhuri, Jeffrey Cooney, Anne-Gaëlle Corbillé, Teodor Danaila, Maria Francesca De Pandis, Sophie Dethy, Rohit Dhall, Ruth Djaldetti, Franck Durif, Stephen Flitman, Eric Freire Alvarez, John Goudreau, Francisco Grandas Perez, Tanya Gurevich, Arnaldo Isa, Jorge L Juncos, Sulada Kanchana, Gabriela Klodowska-Duda, Dariusz Koziorowski, Jaime Kulisevsky Bojarski, Juan Lopez Lozano, Lan Luo, Nataliya Lytvynenko, Roberto Marconi, Ana-Raquel Marques, Juan Carlos Martinez Castrillo, Irene Martinez Torres, Aashoo Mentreddi, Pablo Mir Rivera, Sergii Moskovko, Yuliya Neryanova, Marco Onofrj, Jill Ostrem, Claudio Pacchetti, Nicola Pavese, Clelia Pellicano, Gonzalo Revuelta, Ana Margarida Rodrigues, Ramon Rodriguez, Monika Rudzinska, Nighat Sarwar, Julie Schwartzbard, Laura Scorr, John Slevin, Tatyana Slobodin, Gianfranco Spalletta, Michele Tagliati, Yen Tai, Alessandro Tessitore, Peter Valkovic, Leo Verhagen, Elena Vostrikova, Gilad Yahalom, Zuleykha Zalyalova, Katerina Zarubova, Irina Zhukova
Journal: The Lancet Neurology (2024)
Restaging With Prostate-Specific Membrane Antigen Imaging in Metastatic Castration-Resistant Prostate Cancer: When Seeing More Is Detrimental to Care
Authors: Ravi A. Madan, Evan Y. Yu, Edwin M. Posadas, Richard J. Lee, Fatima Karzai, Peter L. Choyke
Journal: Journal of Clinical Oncology (2024)

#PSMA is amazing new tech but is using it to expedite the call of disease progression helping #ProstateCancer patients?
Association between polymorphisms on chromosome 17q12-q21 and rhinovirus-induced interferon responses
Authors: Eteri Regis, Sara Fontanella, John A. Curtin, Angela Pinot de Moira, Michael R. Edwards, Clare S. Murray, Angela Simpson, Sebastian L. Johnston, Adnan Custovic
Journal: Journal of Allergy and Clinical Immunology (2024)

Background Single nucleotide polymorphisms (SNPs) in genes on chromosome 17q12-q21 are associated with childhood-onset asthma and rhinovirus-induced wheezing. There is little mechanistic data linking chromosome 17q12-q21 to wheezing illness. Objective To investigate whether 17q12-q21 risk alleles may be associated with impaired interferon (IFN) responses to rhinovirus. Methods In a population-based birth cohort of European ancestry, we stimulated peripheral blood mononuclear cells (PBMCs) with rhinovirus-A1 (RV-A1) and rhinovirus-A16 (RV-A16) and measured IFN and IFN-induced chemokine CXCL10/IP10 responses in supernatants. We investigated associations between virus-induced cytokines and six SNPs in 17q12-q21. Bayesian profile regression was applied to identify clusters of individuals with different immune response profiles and genetic variants. Results Five SNPs (in high linkage disequilibrium, r 2 ≥ 0.8 ) were significantly associated with RV-A1-induced IFN-β (rs9303277: P=0.010; rs11557467: P=0.012; rs2290400: P=0.006; rs7216389: P=0.008; rs8079416: P=0.005). A reduction in RV-A1-induced IFN-β was observed among individuals carrying asthma risk alleles. There were no significant associations for RV-A1-induced IFN-α or CXCL10, or for any RV-A16-induced IFN/CXCL10. Bayesian profile regression analysis identified three clusters which differed in IFN-β induction to RV-A1 (low, medium and high). The typical genetic profile of the cluster associated with low RV-A1-induced IFN-β responses was characterised by a very high probability of being homozygous for the asthma risk allele for all SNPs. Children with persistent wheeze were almost 3-times more likely to be in clusters with reduced/average RV-A1-induced IFN- β responses than in the high immune response cluster. Conclusions Polymorphisms on chromosome 17q12-q21 are associated with rhinovirus-induced IFN-β, suggesting a novel mechanism (impaired IFN-β induction) linking 17q12-q21 risk alleles with asthma/wheeze.
TRPV1 analgesics disturb core body temperature via a biased allosteric mechanism involving conformations distinct from that for nociception
Authors: Yi-Zhe Huang, Jing-Xian Ma, Yu-Jing Bian, Qin-Ru Bai, Yu-Hao Gao, Shu-Ke Di, Yun-Tao Lei, Hui Yang, Xiao-Na Yang, Chang-Yan Shao, Wen-Hui Wang, Peng Cao, Chang-Zhu Li, Michael X. Zhu, Meng-Yang Sun, Ye Yu
Journal: Neuron (2024)